• In late February 2026, Immunocore Holdings plc reported fourth-quarter revenue of US$104.48 million and a quarterly net loss of US$30.06 million, while full-year revenue reached US$400.02 million with the annual net loss narrowing to US$35.51 million versus the prior year.
• The results underscore Immunocore’s ability to grow sales and reduce full-year losses even as it continues to invest heavily in advancing its ImmTAX-based pipeline beyond its lead product.
• We’ll now examine how this combination of higher revenue and a smaller full-year loss reshapes Immunocore’s existing investment narrative.

AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Immunocore Holdings Investment Narrative Recap

To own Immunocore, you need to believe that its ImmTAX platform and KIMMTRAK franchise can eventually support a profitable, multi-product business despite ongoing losses. The latest results, with revenue up to US$400.02 million and a narrower full-year net loss of US$35.51 million, support that narrative but do not remove the near term risks around KIMMTRAK reliance and high R&D spend. The most important short term catalyst and risk profile remain broadly unchanged.

The earnings release on 25 February 2026 is most relevant here, as it ties directly to how much financial room Immunocore has to fund late stage trials. While Q4’s larger net loss of US$30.06 million highlights the cost of running three Phase III melanoma programs and earlier pipeline work, the full year improvement in losses gives investors more context for weighing upcoming trial readouts against ongoing cash burn.

Yet, against this progress, investors still need to be aware of the risk that KIMMTRAK’s growth slows before the broader pipeline can...

Immunocore Holdings' narrative projects $551.3 million revenue and $88.5 million earnings by 2028. This requires 15.7% yearly revenue growth and a $108.8 million earnings increase from -$20.3 million today.

Uncover how Immunocore Holdings' forecasts yield a $66.57 fair value, a 104% upside to its current price.

Exploring Other Perspectives

Before this update, the most optimistic analysts were assuming revenue could reach about US$655 million and earnings about US$76 million within a few years, which contrasts sharply with the ongoing reliance on KIMMTRAK and the risk that pricing pressure or trial setbacks could slow that path, reminding you that views on Immunocore’s potential can differ widely and may shift again after these results.

Explore 3 other fair value estimates on Immunocore Holdings - why the stock might be worth just $65.01!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immunocore Holdings research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Immunocore Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunocore Holdings' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.